E Fund Management Co. Ltd. Buys Shares of 5,512 Inhibrx, Inc. (NASDAQ:INBX)

E Fund Management Co. Ltd. purchased a new position in Inhibrx, Inc. (NASDAQ:INBX) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 5,512 shares of the company’s stock, valued at approximately $209,000.

Several other large investors also recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. grew its stake in Inhibrx by 8.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 229,866 shares of the company’s stock valued at $8,735,000 after buying an additional 17,762 shares during the last quarter. AJOVista LLC acquired a new stake in shares of Inhibrx in the fourth quarter valued at about $26,000. Signaturefd LLC increased its stake in shares of Inhibrx by 4,637.5% in the fourth quarter. Signaturefd LLC now owns 758 shares of the company’s stock worth $29,000 after purchasing an additional 742 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Inhibrx by 6.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 20,494 shares of the company’s stock worth $779,000 after purchasing an additional 1,331 shares during the last quarter. Finally, Arizona State Retirement System acquired a new position in shares of Inhibrx during the 4th quarter worth about $209,000. Institutional investors own 82.46% of the company’s stock.

Analysts Set New Price Targets

INBX has been the topic of a number of research analyst reports. JMP Securities reaffirmed a “market perform” rating on shares of Inhibrx in a report on Tuesday, January 23rd. Lifesci Capital downgraded shares of Inhibrx from an “outperform” rating to a “market perform” rating in a research note on Tuesday, January 23rd.

Inhibrx Stock Performance

NASDAQ:INBX opened at $34.69 on Friday. The firm’s 50-day moving average is $34.83 and its 200-day moving average is $31.31. The company has a market cap of $1.81 billion, a price-to-earnings ratio of -6.90 and a beta of 2.87. The company has a debt-to-equity ratio of 4.78, a quick ratio of 5.25 and a current ratio of 5.24. Inhibrx, Inc. has a 52-week low of $14.31 and a 52-week high of $39.79.

Inhibrx (NASDAQ:INBX) last released its earnings results on Wednesday, February 28th. The company reported ($1.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.66). The firm had revenue of $1.63 million for the quarter, compared to analyst estimates of $0.10 million. Inhibrx had a negative return on equity of 590.78% and a negative net margin of 13,408.95%. Equities research analysts anticipate that Inhibrx, Inc. will post -4.34 earnings per share for the current year.

Inhibrx Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.